Hyeonseok Lee1, Seung Baik Han1, Ji Hye Kim1, Soo Kang1, Areum Durey2. 1. Department of Emergency Medicine, Inha University School of Medicine, Incheon, Republic of Korea. 2. Department of Emergency Medicine, Inha University School of Medicine, Incheon, Republic of Korea. Electronic address: arkim1202@inhauh.com.
Abstract
OBJECTIVES: The incidence of urinary tract infection (UTI) due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli has increased over recent years. Initial empirical therapy is often ineffective for these resistant isolates resulting in prolonged hospitalization and increased mortality. This study was conducted to determine the risk factors of UTI caused by ESBL E. coli in the emergency department (ED). METHODS: This is a retrospective case-control study at a university hospital in Korea with UTI patients who visited ED between June 2015 and December 2016. We compared case patients with ESBL E. coli UTI (n = 50) to control patients with non-ESBL-producing E. coli UTI (n = 100), which were matched for age and sex. Multivariate logistic regression analysis was used to explore risk factors. RESULTS: Our study showed that hospital-acquired infection (OR = 3.86; 95% CI = 1.26-11.8; p = .017), prior UTI within 1 year (OR = 3.26; 95% CI = 1.32-8.05; p = .010), and underlying cerebrovascular disease (OR = 3.24; 95% CI = 1.45-7.25; p = .004) were independent risk factors for acquisition of ESBL-producing E. coli. Notably, 35 (70%) out of 50 case patients had community-acquired infection, and 68% and 54% of ESBL E. coli were resistance to ciprofloxacin and trimethoprim-sulfamethoxazole, respectively. On the contrary, 98% of ESBL E. coli was susceptible to amikacin. CONCLUSION: The main risk factors identified in our study should be considered when treating UTI patients in ED. Amikacin may improve the outcome of empirical treatment without increasing carbapenem utilization.
OBJECTIVES: The incidence of urinary tract infection (UTI) due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli has increased over recent years. Initial empirical therapy is often ineffective for these resistant isolates resulting in prolonged hospitalization and increased mortality. This study was conducted to determine the risk factors of UTI caused by ESBL E. coli in the emergency department (ED). METHODS: This is a retrospective case-control study at a university hospital in Korea with UTI patients who visited ED between June 2015 and December 2016. We compared case patients with ESBL E. coli UTI (n = 50) to control patients with non-ESBL-producing E. coli UTI (n = 100), which were matched for age and sex. Multivariate logistic regression analysis was used to explore risk factors. RESULTS: Our study showed that hospital-acquired infection (OR = 3.86; 95% CI = 1.26-11.8; p = .017), prior UTI within 1 year (OR = 3.26; 95% CI = 1.32-8.05; p = .010), and underlying cerebrovascular disease (OR = 3.24; 95% CI = 1.45-7.25; p = .004) were independent risk factors for acquisition of ESBL-producing E. coli. Notably, 35 (70%) out of 50 case patients had community-acquired infection, and 68% and 54% of ESBL E. coli were resistance to ciprofloxacin and trimethoprim-sulfamethoxazole, respectively. On the contrary, 98% of ESBL E. coli was susceptible to amikacin. CONCLUSION: The main risk factors identified in our study should be considered when treating UTI patients in ED. Amikacin may improve the outcome of empirical treatment without increasing carbapenem utilization.
Authors: M C MacKinnon; J M Sargeant; D L Pearl; R J Reid-Smith; C A Carson; E J Parmley; S A McEwen Journal: Antimicrob Resist Infect Control Date: 2020-12-10 Impact factor: 4.887
Authors: Kathryn L McDonald; Sarah Garland; Carolee A Carson; Kimberly Gibbens; E Jane Parmley; Rita Finley; Melissa C MacKinnon Journal: JAC Antimicrob Resist Date: 2021-02-14
Authors: Roel P J Willems; Karin van Dijk; Johannes C F Ket; Christina M J E Vandenbroucke-Grauls Journal: JAMA Intern Med Date: 2020-04-01 Impact factor: 21.873
Authors: Manuel Madrazo; Ana Esparcia; Ian López-Cruz; Juan Alberola; Laura Piles; Alba Viana; José María Eiros; Arturo Artero Journal: BMC Infect Dis Date: 2021-12-07 Impact factor: 3.090